RxDoctor Payments DataLook up a doctor →

Liliya Besedina, MD

Dermatology · Bayonne, NJNPI 1326102609

Payments from drug & device makers

$14,663in general payments, 2019–2025

Across 940 payments — averaging $15.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • LEO Pharma Inc.$3K
  • AbbVie$2K
  • Johnson & Johnson$2K
  • Sun Pharmaceutical Industries Inc.$871
  • Pfizer$867
  • Arcutis Biotherapeutics, Inc.$792
  • plus $6K from 30 others

What the payments were for

  • Consulting fees$7005%
  • Food & beverage$13,66793%
  • Education$2962%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,663 in reported general payments places this provider in the 85th percentile of 394 dermatology providers in New Jersey.

See all dermatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$80,163
Medicare patients
251
Services billed
2,804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa31$616,553
TremfyaGuselkumab25$320,462
Bimzelx AutoinjectorBimekizumab-Bkzx21$292,950
SkyriziRisankizumab-Rzaa14$267,041
OpzeluraRuxolitinib Phosphate138$266,024
Cosentyx Sensoready (2 Pens)Secukinumab30$251,518
Dupixent PenDupilumab49$175,005
JubliaEfinaconazole101$133,585
ZoryveRoflumilast95$95,757
FinaceaAzelaic Acid179$73,808
CrotanCrotamiton36$61,092
VtamaTapinarof36$48,852
Dupixent SyringeDupilumab13$48,115
Pimecrolimus138$41,638
Fluocinonide425$39,952

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$1,532$320,46225 claims
AbbVieSkyrizi$2,053$267,04114 claims
Incyte CorporationOpzelura$227$266,024138 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$736$133,585101 claims
Arcutis Biotherapeutics, Inc.Zoryve$792$95,75795 claims
LEO Pharma Inc.Finacea$2,549$73,808179 claims
Dermavant Sciences, Inc.Vtama$314$48,85236 claims
EPI Health, LLCRhofade$329$10,56818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 394 dermatology providers in New Jersey.

Other dermatology in Bayonne

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →